Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com


Janssen Expands Clinical Development for Tremfya(R) (guselkumab) in Familial Adenomatous

Shots: Janssen has initiated P-Ib proof-of-concept clinical trial assessing Guselkumab vs PBO in 72 patients with familial adenomatous polyposis (FAP). With the initiation of P-Ib study for FAP, MorphoSys will receive milestones from Janssen Earlier, Janssen collaborated with MorphoSys to develop Guselkumab utilizing MorphoSys’s HuCAL antibody technology (Human Combinatorial Antibody Library), a platform for invitro […]Read More


Santhera to Present Result of DELOS & SYROS Study at

Shots: The P-III DELOS study involves assessing of Idebenone (900 mg/day) vs PBO in 64 patients with Duchenne muscular dystrophy (DMD) for 52wks. & P-II DELPHI study with 2-year extension study (DELPHI-E). SYROS study involves assessing of Idebenone (900 mg/day) in 18 patients under Expanded Access Programs (EAPs) who completed the DELOS study The P-III […]Read More


Dr. Reddy’s to Acquire a Portfolio of 42 Abbreviated New

Shots: Dr. Reddy’s acquires a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications (ANDAs) in the US, including >30 generics injectable The focus of the acquisition is to enhance Dr. Reddy’s injectable portfolio in the US and globally Dr. Reddy’s will launch the products within the next one to two years and according to […]Read More


Alnylam Reports Results of Givosiran in P-III ENVISION Study to

Shots: The P-III ENVISION study involves assessing of Givosiran vs PBO in patients with acute hepatic porphyria (AHP) ENVISION study results:74% mean reduction of annualized rate of porphyria attacks; 90% median reduction in composite annualized attack rate (AAR); overall safety and tolerability; AEs (89.6% vs 80.4%); attack free (50% vs 16.3%); @3/6mos. 91%/83% in urinary […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (April 08-12, 2019)

1.Omron Healthcare Receives FDA’s Approval for Complete a Blood Pressure Monitoring Device with ECG Facility Published: April 12, 2019 | Tags: Omron Healthcare, Receives, FDA, Approval, Complete, Blood Pressure, Monitoring, Device, EKG, Facility 2.Gilead and Novo Nordisk Collaborate to Conduct a Combination Therapy Trial in NASH Published: April 12, 2019 | Tags: Gilead, Novo Nordisk, Collaborate, Conduct, […]Read More


Cognoa Signs an Exclusive License Agreement with Stanford for its

Shots: Cognoa to get exclusive license rights for Stanford’s Google Glass-based autism technology to develop & commercialize digital therapies for children with autism spectrum disorder (ASD) The Superpower Glass (SG) intervention deployed via Google Glass and a mobile app is evaluated in 71 children with ASD and resulted in improvement in socialization, play and coping […]Read More